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ABSTRACT 
We have previously reported the feasibility of allogeneic CD34-selected PBSC 
transplantation followed by pre-emptive CD8-depleted DLI (study group). In this report, we 
retrospectively compare the clinical outcome of the 24 patients included in this study with an 
historical group of 35 patients receiving unmanipulated marrow (BMT group). Patients in the 
study group had significantly faster neutrophil and platelet recovery and were discharged 
earlier than BMT patients. The actuarial 150-day (after DLI) probability of developing grade II-
IV acute GVHD was 28% for the study group versus 62% for the BMT group (p=0.002). The 
actuarial 2-yr probability of developing chronic GVHD was similar (37% versus 36% (NS)) but 
chronic GVHD was significantly delayed in the study group (p=0.003). The actuarial 2-yr 
probability of relapse was 30% in the study group versus 33% in the BMT group (NS). The 
actuarial 2-yr probability of survival was 45% in the study group versus 43% in the BMT group 
(NS). We conclude that allogeneic transplantation of CD34-selected PBSC followed by pre-
emptive CD8-depleted DLI is feasible with rapid engraftment and minimizes the risk of severe 
GVHD. Large prospective trials are required to confirm these results.  
 
Key words: Allogeneic transplantation, GVHD, GVL, CD34 selection, donor lymphocyte 
infusions. 
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INTRODUCTION 
Graft-versus-host host disease (GVHD) is a life-threatening complication of allogeneic 
hematopoietic stem cell transplantation (HSCT)1;2. It is due to donor lymphocytes co-
transplanted with donor stem cells that are primed by histocompatibility differences between 
donors and recipients and activated by a cytokine storm caused by the conditioning regimen3. 
The most efficient method for prevention of GVHD consists in T-cell depletion (TCD) of the 
graft4;5. However, this usually leads to an increased risk of leukemia relapse because of the loss 
of the graft-versus-leukemia (GVL) effect6-8. To lessen the impact of TCD on leukemia relapse, 
several groups have studied the feasibility of preemptive donor lymphocyte infusion (DLI) 
given several weeks to months after the transplant, i.e. after the cytokine storm and after the 
patient has recovered from conditioning-regimen related toxicities 9-16. Two of them have 
shown that pre-emptive DLI induced a strong GVL effect 13;14 but it remains to be 
demonstrated whether this strategy effectively decreases the incidence of GVHD.  
Previous studies have demonstrated that it is possible to maintain a GVL effect without 
GVHD by CD8-depletion of DLI given for leukemic relapse after BMT17-19. Therefore, we 
have recently developed an original strategy of pre-emptive infusions of CD8-depleted donor 
lymphocytes given in incremental doses after CD34-selected peripheral blood stem cell 
transplantation (PBSCT) 16. In this article, we retrospectively compare the clinical outcome of 
the 24 patients included in this study with an historical group of 35 patients receiving 
unmanipulated marrow (BMT group) for similar hematological malignancies.
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PATIENTS AND METHODS 
 
Patients and donors 
 Twenty-four patients with hematologic malignancies, 18 males and 6 females, aged 14 
to 56 yrs (median 46 yrs) were included in the study group. Twelve patients (7 AML, 2 ALL 
and 1 NHL in first remission and 2 CML in first chronic phase) were designated as standard 
risk for relapse although 4 had poor prognostic cytogenetic abnormalities. The remaining 12 
patients with more advanced disease were considered as high risk, including an ALL patient in 
first CR because of the very high number of lymphoblasts and massive cerebral leucostasis at 
diagnosis. Transplants were carried out from matched (N=16) or one-mismatch (N=8) related 
donors (table 1). Written informed consent was obtained from patients and donors and our 
institution’s Ethical Committee approved the protocol. Results were compared with an 
historical group including all patients transplanted after 1991 with unmanipulated allogeneic 
bone marrow from related donors for diseases also included in the study group (BMT group, 
N=35) (table 1). Twenty patients (12 AML and 4 ALL in first remission and 4 CML in first 
chronic phase) were considered as standard risk. The remaining 15 patients with more 
advanced disease were considered as high risk.  
 
Clinical management 
 Hematopoietic stem cells were infused on day 0 through a Hickman catheter after a 
TBI-based or busulfan-based conditioning regimen.  All patients in the study group (versus 
only 13 in the BMT group, p < 0.001) were treated with 5 µg/kg/d lenogastrim (Granocyte) 
from day +1 until the granulocyte count was > 109/L for three consecutive days or > 1010/L for 
one day. Six of the first 9 patients in the study group (4 not HLA-identical to their donor and 2 
AML in CR1) received short methotrexate in addition to cyclosporine. Because of the low 
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incidence of acute GVHD observed in the first 9 patients, GVHD prophylaxis was carried out 
with CyA alone for patients 10 to 24. A smaller proportion (11/35, p<0.001) of the patients in 
the BMT group received CyA alone as GVHD prophylaxis because of their young age and high 
risk of post-transplant relapse. The diagnosis and grading of acute and chronic GVHD was 
established as previously reported20;21;21. Disease evaluation, including bone marrow aspirations 
and biopsies were routinely carried out on days 40, 100, 180 and 365.  
 
Stem cell and lymphocyte collection, selection and infusion 
 Bone marrows were collected from the posterior iliac crest under general anesthesia and 
infused unmanipulated into recipients on the day of harvest. In case of minor and/or major 
ABO incompatibility, plasma and/or RBC were removed before infusion. For PBSC 
collections, donors received human G-CSF (Granocyte, kindly provided by Rhone-Poulenc-
Roerer, Brussels, Belgium) at 10-15 µg/kg from day -5 through day -1. PBSC were collected 
on days -1 and 0, pooled, and CD34-selected using the Isolex 300i magnetic cell separator 
(Baxter-Fenwall Laboratories, Deerfield, IL), as previously reported16;22.  
 Around day 60 post-PBSCT, donor lymphocytes were collected on 2 consecutive days, 
pooled and submitted to CD8-selection using the Nexell Isolex 300i, as previously 
described16. The CD8-negative fraction was recovered and divided into 3 aliquots containing 2 
x 106, 1 x 107 and 5 x 107 CD3+ cells/kg recipient for patients 1 to 13 or into 2 aliquots of 1 x 
107 and 5 x 107 CD3+ cells/kg recipient for patients 14 to 21. Aliquot 1 was injected fresh 
immediately after the CD8 depletion procedure (around day 60). Around day 100 (and 140 for 
patients 1 to 13), cryopreserved aliquots 2 (and 3) were thawed and infused into the patient. 
CD8-depleted DLI were not to be infused in case of an antecedent grade III or IV acute GVHD, 
or an antecedent of extensive chronic GVHD, or active GVHD at time of scheduled infusion. 
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Statistical analyses 
 The probability of GVHD, relapse, and survival as well as the speed of engraftment 
were studied by life-table analyses and Wilcoxon rank tests were used for comparisons between 
groups. Statistical analyses were carried out with Graphpad Prism (Graphpad Software, San 
Diego, CA). 
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RESULTS 
 
Engraftment kinetics  
 The median time to achieve an absolute neutrophil count of 0.5x109/L was 11 days for 
the study group versus 22 days in the BMT group (p<0.001) (Figure 1A). Median times to 20 x 
109/L platelets were 13 versus 24 days (p=0.004) (Figure 1B) and median times to 1% 
reticulocytes 17 versus 25 days (p=0.005) (Figure 1C). Median time to hospital discharge was 
21 days for the study group versus 36 days for the BMT group (p=0.010) (Figure 1D). 
 
 Graft-versus-host disease 
The study group had a higher proportion of patients over the age of 40 (63% vs 37%, 
p=0.055) and a higher proportion of mismatched transplants (33% versus 14%, p=0.082), and 
thus a larger proportion of patients at high risk of GVHD (75% vs 43%, p=0.015). Furthermore, 
the study group had more frequent omission of MTX as part of the GVHD prophylaxis (75% 
versus 31%, p<0.001). Therefore, the study group was considered at higher risk of GVHD (at 
least one of these 3 factors present) than the BMT group (p=0.010).   
Twenty-six of the 35 patients in the BMT group developed acute GVHD (6 grade I, 9 
grade II, 8 grade III and 3 grade IV) compared with 14/24 patients in the study group (9 grade 
I, 5 grade II and 1 grade IV). Before DLI, the actuarial 60 days incidence of grade II-IV acute 
GVHD was 17% for the study group versus 62% for the BMT group (p<0.001). After DLI, the 
actuarial 150-day probability of developing grade II-IV acute GVHD was 28% for the study 
group versus 62% for the BMT group (p=0.002) (Figure 2A). For HLA-identical sibling 
transplant recipients, the figures were 13% versus 55% (p=0.006).  
The actuarial 2-yr probability of developing chronic GVHD was similar (37% versus 
36% (NS)) but chronic GVHD was significantly delayed in the study group (p=0.003) (figure 
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2B). For HLA-identical sibling transplant recipients, the figures were 12% in the study group 
versus 33% in the BMT group (p=0.16). Among at-risk patients (surviving beyond day 100), 
the incidence of extensive chronic GVHD was lower in the study group (1/18 or 6% vs 9/26 or 
35%, p=0.024). Their actuarial 2-yr rates were 13% and 36%, respectively (p=0.031). For 
HLA-identical siblings, the figures were 0% (0/11) in the study group versus 32% in the BMT 
group (7/22) (p=0.035). The actuarial 2-yr rates were 0% and 33%, respectively (p=0.06). 
 
Relapse, transplant-related mortality and overall survival 
The actuarial 2-yr probability of relapse was 30% in the study group versus 33% in the 
BMT group (NS) (Figure 3A). For malignancies other than ALL, the figures were 14% and 
37%, respectively (p=0.2). Three of 5 ALL patients in the study group versus none of 7 in the 
BMT group relapsed (p=0.055). This could be partially explained by the occurrence of grade II-
IV GVHD in 1/5 patients in the study group versus 5/7 in the BMT group.  
Non-relapse causes of death were multiple organ failure (N=2), sudden death at home 
(N=2), GVHD (N=1), interstitial pneumonia (N=1), veno-occlusive disease of the liver (N=1) 
and toxic hepatic failure (N=1) in the study group and GVHD (N=5), interstitial pneumonia 
(N=3), veno-occlusive disease of the liver (N=1) and multiple organ failure (N=1) in the BMT 
group. The actuarial 1-yr probability of transplant-related mortality was 34% in the study group 
versus 33% in the BMT group. 
The actuarial 2-yr probability of survival was 45% in the study group versus 43% in the 
BMT group (NS) (Figure 3B). For standard risk patients, disease-free survival was 64% in the 
study group versus 55% in the BMT group (NS). For high-risk patients the figures were 18% 
and 27%, respectively (NS). 
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DISCUSSION 
Several reports have demonstrated that hematologic recovery was faster after PBSC 
transplantation compared with BMT23-25. In our study, neutrophil, erythrocyte and platelet 
engraftments were significantly faster in the study than in the BMT group, although faster 
neutrophil engraftment could be partly due to more common use of G-CSF in the study group. 
This faster hematologic recovery permitted to discharge study group patients significantly 
faster than patients of the BMT group. 
As previously suggested by others26, our results show that CD34-selection reduces the 
risk of acute GVHD. The actuarial 60-day (before DLI) probability of grade II-IV acute GVHD 
was 17% in our study. This rate compares very favorably with our historical BMT group (62%, 
p<0.001) and with studies of HLA-identical siblings receiving unmanipulated PBSC or 
BM24;25. For example in the most recent report of the Seattle group25, the 100-day incidence of 
grade II-IV acute GVHD was 64% in the PBSC group and 57% in the BM group. Our 55% rate 
of acute GVHD in HLA-identical siblings undergoing BMT (including the one third of our 
BMT patients who did not receive short MTX) is comparable to the 57% incidence reported 
recently by the Seattle group with cyclosporine and short methotrexate25. In addition, the 
occurrence of chronic GVHD was considerably delayed compared to BMT recipients (Figure 
2), indicating that it occurred more as a result of DLI rather than of the CD34-selected graft. 
This took place despite the higher proportion of mismatched transplants and older patients in 
our study group as well as the lower use of MTX in addition to CyA for GVHD prophylaxis.  
Recent evidence implicates a preparative regimen-related “cytokine storm” in the 
pathogenesis of acute GVHD following HSCT1;3. Therefore, delaying the infusion of donor 
lymphocytes after this storm has subsided could result in a lower risk of acute GVHD27. The 
feasibility of T-cell depletion of the graft followed by preemptive DLI was first demonstrated 
by the Jerusalem’s group9. Since them, several other studies have also investigated the infusion 
Baron et al., page 10 
of T cells, a few weeks to a few months after T-cell depleted transplantation 10-16. However, 
although the final goal of these approaches is to decrease the risk of graft-versus-host disease 
without compromising the GVL effect, none of them has compared the incidence of GVHD 
after TCD HSCT followed by pre-emptive DLI with a cohort of patients receiving 
unmanipulated HSCT. In our study group, 19/24 patients received pre-emptive CD8-depleted 
DLI and DLI were never withheld because of GVHD. These DLI were very well tolerated in 
patients 1-13 (only 4 patients developed grade II acute GVHD) leading us to omit short MTX 
even in mismatched or older patients and then to infuse higher doses of CD8-depleted donor 
lymphocytes earlier in patients 13-24. These doses again did not induce any severe acute 
GVHD except in patient 21 who developed grade IV acute GVHD and died of infection and 
GVHD. Although low doses of CD8+ cells were infused because the degree of CD8+ cell 
depletion was moderate (only 1.5 log) and although we injected more CD4+ cells because the 
total dose of T cells was maintained at 5 x 107/kg, the procedure was efficient to prevent severe 
GVHD. Compared with our historical BMT group, the probabilities of grade II-IV acute 
GVHD and of extensive chronic GVHD were significantly lower. This was achieved despite 
the higher proportion of mismatched and older transplant recipients, resulting in a higher 
theoretical risk of developing severe GVHD. For HLA-identical sibling transplants, the 
incidence of grade II-IV acute GVHD, chronic GVHD and extensive chronic GVHD were 
13%, 12% and 0%, respectively. These incidences are lower than previously reported in HLA-
identical BMT with MTX and CyA as GVHD prophylaxis 28and even more so in HLA-
identical PBSCT24;25. Therefore, our results show that it is possible to circumvent GVHD by 
delaying the addition of donor lymphocytes after CD34-selected transplantation. 
 The mechanisms and specificity of the GVL reaction remain uncertain7;29. Although the 
contribution of CD8+ T cells cannot be dismissed, CD4+ T cells are believed to be the primary 
mediators of GVL18;30. Therefore, pre-emptive infusion of large doses of CD4+ (and NK) cells 
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in our study should be expected to preserve the GVL effect. Indeed, the relapse rate was 
comparable to that of our historical BMT group, although obviously both groups were quite 
heterogeneous for initial diagnosis and clinical status before transplant. The relapse rate was 
also much lower than previously described after T cell depleted transplantation31. We observed 
no relapse in the standard risk patients and only 50% relapses in the high-risk patients. 
Interestingly, whereas previous studies have shown that the persistence of BCR-ABL 
transcripts after TCD BMT strongly predicted for relapse, recurrence of CML could be 
prevented by DLI in one such patient16. More ALL patients in the study group relapsed 
compared to the BMT group. This finding could be partially explained by the lower occurrence 
of grade II-IV GVHD in the study group. It is well demonstrated that the risk of relapse is 
much lower in ALL patients who developed grade II-IV acute GVHD but paradoxically is not 
affected by T-cell depletion of the graft32. Thus, it is possible that a strategy to separate the 
GVL effect from GVHD may not be successful in ALL patients.  
 We conclude that allogeneic CD34-selected PBSCT followed by pre-emptive CD8-
depleted DLI appears to be a promising strategy to separate the GVL effect from GVHD. 
CD34-selection of the graft and CD8-depletion of DLI resulted in substantial benefits for the 
patients in terms of acute and chronic GVHD despite the large proportion of HLA mismatches. 
The use of pre-emptive DLI appeared to maintain the GVL effect in a high-risk population but 
this remains to be demonstrated in more homogenous groups of patients. Large randomized 
studies are needed to determine whether this strategy could improve overall survival as well as 
the quality of life of the patients.  
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Legends to the figures 
 
 
Figure 1. A. Time to 500 neutrophils/µL after BMT (N=35) or CD34-selected PBSCT (N=24).  
     B. Time to 20 000 platelets/µL after BMT (N=35) or CD34-selected PBSCT (N=24).  
     C. Time to 1% reticulocytes after BMT (N=35) or CD34-selected PBSCT (N=24).  
     D. Time to hospital discharge after BMT (N=35) or CD34-selected PBSCT (N=24). 
 
Figure 2. A. Cumulative incidence of grade II-IV acute GVHD after BMT (N=35) or CD34-
selected PBSCT followed by CD8-depleted DLI (N=24). 
      B. Cumulative incidence of chronic GVHD after BMT (N=35) or CD34-selected 
PBSCT followed by CD8-depleted DLI (N=24). 
 
Figure 3. A. Cumulative incidence of relapse after BMT (N=35) or CD34-selected PBSCT 
followed by CD8-depleted DLI (N=24). 
B. Survival rates of patients grafted with bone marrow (N=35) or CD34-selected 
PBSCT followed by CD8-depleted DLI (N=24). 
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Table 1. Characteristics of the two groups of patients  
 
 Study Group BMT Group 
No of patients 24 35 
Median age in years (range) 
    Recipients 
    Donors 
Recipient sex (F/M) 
Donor sex (F/M) 
HLA compatibility 
      Identical 


















Acute myeloid leukemia 
      CR1 
      CR2 
      Relapse 
      Refractory 
Acute lymphoid leukemia 
      CR1 
      CR2 
      Relapse 
Chronic myeloid leukemia 
      CP1 
      CP2 
      Blast crisis 
Non-Hodgkin’s lymphoma 
      CR1 
      CR2 





































Chronic lymphocytic leukemia 
      Refractory 
Myelodysplastic syndrome 
      Relapse 











Risk for relapse 
      Low risk 
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G-CSF post-transplant 24 13 
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